Ambu A/S

CPSE:AMBU B Stock Report

Market Cap: DKK 17.9b

Ambu Valuation

Is AMBU B undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of AMBU B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: AMBU B (DKK68.6) is trading below our estimate of future cash flow value (DKK147.23)

Significantly Below Future Cash Flow Value: AMBU B is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AMBU B?

Key metric: As AMBU B is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for AMBU B. This is calculated by dividing AMBU B's market cap by their current earnings.
What is AMBU B's PE Ratio?
PE Ratio37.9x
EarningsDKK 477.00m
Market CapDKK 17.88b

Price to Earnings Ratio vs Peers

How does AMBU B's PE Ratio compare to its peers?

The above table shows the PE ratio for AMBU B vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average35.6x
EMBLA Embla Medical hf
20x12.55%DKK 11.2b
DEMANT Demant
24.2x12.36%DKK 57.3b
COLO B Coloplast
42.9x25.19%DKK 90.2b
301363 MeHow Innovative
55.2x24.97%CN¥15.9b
AMBU B Ambu
37.9x23.75%DKK 18.1b

Price-To-Earnings vs Peers: AMBU B is expensive based on its Price-To-Earnings Ratio (37.9x) compared to the peer average (35.6x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does AMBU B's PE Ratio compare vs other companies in the European Medical Equipment Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
AMBU B 37.9xIndustry Avg. 27.0xNo. of Companies12PE01632486480+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: AMBU B is expensive based on its Price-To-Earnings Ratio (37.9x) compared to the European Medical Equipment industry average (27x).

Price to Earnings Ratio vs Fair Ratio

What is AMBU B's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AMBU B PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio37.9x
Fair PE Ratio30.6x

Price-To-Earnings vs Fair Ratio: AMBU B is expensive based on its Price-To-Earnings Ratio (37.9x) compared to the estimated Fair Price-To-Earnings Ratio (30.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst AMBU B forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentDKK 68.55
DKK 87.30
+27.35%
22.70%DKK 116.40DKK 58.00n/a8
Jul ’27DKK 64.20
DKK 87.30
+35.98%
22.70%DKK 116.40DKK 58.00n/a8
Jun ’27DKK 65.65
DKK 88.80
+35.26%
20.17%DKK 116.40DKK 65.00n/a8
May ’27DKK 65.45
DKK 105.30
+60.89%
16.18%DKK 138.00DKK 78.00n/a8
Apr ’27DKK 69.05
DKK 110.79
+60.44%
16.52%DKK 138.00DKK 78.00n/a7
Mar ’27DKK 79.50
DKK 112.21
+41.15%
15.85%DKK 138.00DKK 78.00n/a7
Feb ’27DKK 85.10
DKK 113.93
+33.88%
12.92%DKK 138.00DKK 90.00n/a7
Jan ’27DKK 88.00
DKK 114.79
+30.44%
13.56%DKK 139.00DKK 90.00n/a7
Dec ’26DKK 86.00
DKK 115.59
+34.40%
13.78%DKK 139.00DKK 90.00n/a7
Nov ’26DKK 100.70
DKK 131.84
+30.93%
14.62%DKK 147.00DKK 90.00n/a7
Oct ’26DKK 101.20
DKK 129.40
+27.87%
14.39%DKK 147.00DKK 90.00n/a7
Sep ’26DKK 96.30
DKK 130.70
+35.72%
13.83%DKK 147.00DKK 90.00n/a7
Aug ’26DKK 92.00
DKK 130.70
+42.07%
13.83%DKK 147.00DKK 90.00n/a7
Jul ’26DKK 98.65
DKK 130.70
+32.49%
13.83%DKK 147.00DKK 90.00DKK 64.207
Jun ’26DKK 101.30
DKK 135.28
+33.54%
13.38%DKK 148.20DKK 90.00DKK 65.658
May ’26DKK 116.50
DKK 141.89
+21.79%
16.57%DKK 165.00DKK 90.00DKK 65.457
Apr ’26DKK 117.95
DKK 141.89
+20.29%
16.57%DKK 165.00DKK 90.00DKK 69.057
Mar ’26DKK 131.50
DKK 143.31
+8.98%
16.92%DKK 165.00DKK 90.00DKK 79.507
Feb ’26DKK 134.75
DKK 143.31
+6.36%
16.92%DKK 165.00DKK 90.00DKK 85.107
Jan ’26DKK 104.00
DKK 127.70
+22.79%
18.51%DKK 160.00DKK 76.00DKK 88.007
Dec ’25DKK 111.00
DKK 127.63
+14.98%
18.51%DKK 160.00DKK 76.00DKK 86.007
Nov ’25DKK 129.70
DKK 128.67
-0.80%
18.50%DKK 145.00DKK 76.00DKK 100.706
Oct ’25DKK 130.00
DKK 125.50
-3.46%
19.14%DKK 145.00DKK 76.00DKK 101.206
Sep ’25DKK 127.95
DKK 126.40
-1.21%
21.87%DKK 160.00DKK 76.00DKK 96.305
Aug ’25DKK 140.60
DKK 117.00
-16.79%
24.96%DKK 138.00DKK 59.00DKK 92.005
Jul ’25DKK 136.55
DKK 117.00
-14.32%
24.96%DKK 138.00DKK 59.00DKK 98.655
DKK 87.3
Fair Value
21.4% undervalued intrinsic discount
8
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/10 17:14
End of Day Share Price 2026/07/10 00:00
Earnings2026/03/31
Annual Earnings2025/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ambu A/S is covered by 14 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
Michael HealyBerenberg
Susannah LudwigBernstein